Indication
Treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy.
In other countries
The same active substances on other registers, the same brand first.
National listings
The national registers that list this EU medicine.
- DacogenBrazil · Janssen-Cilag Farmacêutica LtdaSame brand
- DacogenCanada · 50 MG / VIAL · Powder · Otsuka Pharmaceutical Co LTDSame brand
- DACOGEN 50 mg polvo para concentrado para solucion para perfusionSpain · 50 mg · polvo para concentrado para solución para perfusión · Janssen-Cilag International N.VSame brand
- DacogenCroatiaSame brand